Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6841

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy; Procedure · Other · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 895
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions: Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Ipilimumab, Multigated Acquisition Scan, Nivolumab, Quality-of-Life Assessment, Trametinib Dimethyl Sulfoxide; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 838
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 528 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib oral treatment, Ocrelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 45
States / cities: Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 40 more

Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 90
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 78 more

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7,458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1655
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more

Conditions: Persistent Atrial Fibrillation
Interventions: FARAPULSE™ Pulsed Field Ablation System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Mobile, Alabama • Jonesboro, Arkansas • Los Angeles, California + 29 more

Conditions: Obesity or Overweight
Interventions: Maridebart Cafraglutide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 53
States / cities: Pelham, Alabama • Chandler, Arizona • Sun City, Arizona + 45 more

Conditions: Ulcerative Colitis
Interventions: Hyperbaric Oxygen Therapy, Sham Hyperbaric Air; Device · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 9 more

Conditions: Operator Radiation Exposure
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Orlando, Florida • Atlanta, Georgia • Rochester, Minnesota + 1 more

Conditions: Major Depressive Disorder
Interventions: Placebo, DT120; Other · Drug
Lead sponsor: Definium Therapeutics US, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Little Rock, Arkansas • Orange, California • San Diego, California + 25 more

Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions: TAK-788, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 11
States / cities: Long Beach, California • Orange, California • Palo Alto, California + 6 more

Conditions: Ulcerative Colitis
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 120
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 103 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC)

Operator Radiation Exposure During Image-Guided Robotic-Assisted Bronchoscopy: A Multicenter Prospective Cohort Study

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis